Takeda Pharmaceutical (NYSE:TAK) cut to “hold” at Jefferies Financial Group

Takeda Pharmaceutical (NYSE:TAK- Get a rating) was downgraded by research analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a note released Friday to investors, Fly reports.

Several other research companies have also published reports on TAK. Cowen upgraded Takeda Pharmaceutical from a “market performance” rating to an “outperform” rating and raised its price target for the company from $21.00 to $24.00 in a Tuesday 19 research note. July. Cowen upgraded Takeda Pharmaceutical from a “market performance” rating to an “outperform” rating in a Tuesday, July 19 research note. Three investment analysts gave the stock a hold rating and two gave the company a buy rating. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $24.00.

Performance of Takeda Pharmaceutical Stocks

Shares of TAK fell $0.20 on Friday, hitting $14.61. 536,986 shares of the company have been traded, compared to its average volume of 2,755,832. The company has a current ratio of 1.21, a quick ratio of 0.81 and a debt ratio of 0.73. The stock has a market capitalization of $46.23 billion, a PE ratio of 17.19, a PEG ratio of 0.60 and a beta of 0.70. The stock’s 50-day simple moving average is $14.13 and its two-hundred-day simple moving average is $14.51. Takeda Pharmaceutical has a 52-week low of $13.05 and a 52-week high of $17.31.

Takeda Pharmaceutical (NYSE:TAK- Get a rating) last reported quarterly earnings data on Wednesday, May 11. The company reported earnings per share of $0.38 for the quarter. Takeda Pharmaceutical had a return on equity of 12.20% and a net margin of 8.44%. The company had revenue of $7.19 billion in the quarter. On average, analysts expect Takeda Pharmaceutical to post 2.2 earnings per share for the current fiscal year.

Institutional investors weigh in on Takeda Pharmaceutical

Several hedge funds and other institutional investors have recently changed their stock holdings. Private Capital Group LLC increased its stake in Takeda Pharmaceutical by 79.8% in the 1st quarter. Private Capital Group LLC now owns 1,865 shares of the company worth $27,000 after purchasing an additional 828 shares during the period. Herold Advisors Inc. bought a new position in shares of Takeda Pharmaceutical during Q1 worth approximately $29,000. Northwestern Mutual Wealth Management Co. increased its holdings of Takeda Pharmaceutical shares by 217.8% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 2,730 shares of the company valued at $39,000 after buying 1,871 additional shares in the last quarter. Addison Advisors LLC purchased a new stake in Takeda Pharmaceutical stock during Q1 worth approximately $48,000. Finally, CWM LLC increased its position in Takeda Pharmaceutical shares by 102.4% during the second quarter. CWM LLC now owns 3,615 shares of the company valued at $51,000 after purchasing an additional 1,829 shares in the last quarter. 2.40% of the shares are currently held by hedge funds and other institutional investors.

Takeda Pharmaceutical Company Profile

(Get a rating)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing and licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the fields of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematological disorders, and hereditary angioedema, as well as plasma-derived therapies and vaccines.

Read more

The Fly logo

Analyst Recommendations for Takeda Pharmaceutical (NYSE:TAK)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Takeda Pharmaceutical right now?

Before you consider Takeda Pharmaceutical, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market spreads…and Takeda Pharmaceutical wasn’t on the list.

Although Takeda Pharmaceutical currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here